Literature DB >> 16621076

Daily organ tracking in intensity-modulated radiotherapy of prostate cancer using an electronic portal imaging device with a dose saving acquisition mode.

Daniel Vetterli1, Sandrine Thalmann, Frank Behrensmeier, Ludger Kemmerling, Ernst J Born, Roberto Mini, Richard H Greiner, Daniel M Aebersold.   

Abstract

BACKGROUND AND
PURPOSE: Daily use of conventional electronic portal imaging devices (EPID) for organ tracking is limited due to the relatively high dose required for high quality image acquisition. We studied the use of a novel dose saving acquisition mode (RadMode) allowing to take images with one monitor unit per image in prostate cancer patients undergoing intensity-modulated radiotherapy (IMRT) and tracking of implanted fiducial gold markers. PATIENTS AND METHODS: Twenty five patients underwent implantation of three fiducial gold markers prior to the planning CT. Before each treatment of a course of 37 fractions, orthogonal localization images from the antero-posterior and from the lateral direction were acquired. Portal images of both the setup procedure and the five IMRT treatment beams were analyzed.
RESULTS: On average, four localization images were needed for a correct patient setup, resulting in four monitor units extra dose per fraction. The mean extra dose delivered to the patient was thereby increased by 1.2%. The procedure was precise enough to reduce the mean displacements prior to treatment to < o =0.3 mm.
CONCLUSIONS: The use of a new dose saving acquisition mode enables to perform daily EPID-based prostate tracking with a cumulative extra dose of below 1 Gy. This concept is efficiently used in IMRT-treated patients, where separation of setup beams from treatment beams is mandatory.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621076     DOI: 10.1016/j.radonc.2006.03.005

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer.

Authors:  Pirus Ghadjar; Nicole Gwerder; Peter Manser; Jacqueline Vock; Axel Madlung; Roberto Mini; Daniel M Aebersold
Journal:  Strahlenther Onkol       Date:  2010-11-30       Impact factor: 3.621

2.  Clinical implications of a prostate-specific antigen bounce after radiation therapy for prostate cancer.

Authors:  Arash O Naghavi; Tobin J Strom; Kevin Nethers; Alex A Cruz; Nicholas B Figura; Kushagra Shrinath; Binglin Yue; Jongphil Kim; Matthew C Biagioli; Daniel C Fernandez; Randy V Heysek; Richard B Wilder
Journal:  Int J Clin Oncol       Date:  2014-09-06       Impact factor: 3.402

3.  Dosimetric coverage of the prostate, normal tissue sparing, and acute toxicity with high-dose-rate brachytherapy for large prostate volumes.

Authors:  George Yang; Tobin J Strom; Richard B Wilder; Kushagra Shrinath; Eric A Mellon; Daniel C Fernandez; Matthew C Biagioli
Journal:  Int Braz J Urol       Date:  2015 May-Jun       Impact factor: 1.541

4.  Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking.

Authors:  Pirus Ghadjar; Jacqueline Vock; Daniel Vetterli; Peter Manser; Roland Bigler; Jan Tille; Axel Madlung; Frank Behrensmeier; Roberto Mini; Daniel M Aebersold
Journal:  Radiat Oncol       Date:  2008-10-20       Impact factor: 3.481

5.  A technique for reducing patient setup uncertainties by aligning and verifying daily positioning of a moving tumor using implanted fiducials.

Authors:  Christopher Nelson; Peter Balter; Rodolfo C Morice; Bum Choi; Rajat J Kudchadker; Kara Bucci; Joe Y Chang; Lei Dong; Susan Tucker; Sastry Vedam; Tina Briere; George Starkschall
Journal:  J Appl Clin Med Phys       Date:  2008-10-30       Impact factor: 2.102

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.